Feasibility of clinical implementation and acceptability of patient-reported screening for chemotherapy-induced peripheral neuropathy (CIPN)
Authors:
Open Access
- 8 October 2026
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (11) , 1073
Abstract
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side-effect of cancer treatment, leading to early treatment cessation and long-lasting disability. This project aimed to determine acceptability and barriers of routine CIPN screening. Methods: In a prospective sample across two sites, patients scheduled for treatment or treated with neurotoxic therapy were eligible to complete CIPN screening at any cycle. Three brief patient-reported outcome screening tools (NCI-PRO-CTCAE, PNQ, and EviQ) and a short feasibility questionnaire were deployed (termed CIPN-Screen) during appointments (Centre 1) or via automated text messages (Centre 2). Results: Seven hundred fifty-five screens were undertaken in 159 participants between March 2022 and November 2023, with 109 at Centre 1 (median[IQR] 1[1]screen) and 646 at Centre 2 (median[IQR] 8[6]screens). Automatic text message reminders at Centre 2 enabled longitudinal assessments to be collected. 426 screens (56.4%) identified CIPN symptoms with 138 (18.3%) moderate-to-severe. Most respondents reported that the CIPN-Screen was easy to complete (92.0%, n = 671), easy to understand (91.6%, n = 668), and helpful to describe symptoms (85.6%, n = 624). Acceptability did not differ by age, sex, or chemotherapy type; however, acceptability did differ according to CIPN symptom severity ( P = 0.0002). There were significant differences in CIPN symptom score over time ( P < 0.0001, n = 52), indicating that the CIPN-Screen detected symptom evolution over time. Conclusion: Questionnaire-based CIPN screening is feasible and assists in symptom profiling for patients treated with neurotoxic chemotherapy. Implications for cancer survivors: CIPN is an important toxicity with lasting effects for cancer survivors. Identifying better approaches to patient-relevant CIPN screening will enable improved care for cancer survivors.Keywords
This publication has 30 references indexed in Scilit:
- Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following ChemotherapyJAMA Network Open, 2024
- Getting ready for real‐world use of electronic patient‐reported outcomes (ePROs) for patients with cancer: A National Comprehensive Cancer Network ePRO Workgroup paperCancer, 2023
- The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice GuidelineAnnals of Oncology, 2022
- Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathySupportive Care in Cancer, 2022
- Chemotherapy and peripheral neuropathyNeurological Sciences, 2021
- Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferencesSupportive Care in Cancer, 2021
- What factors influence organisational readiness for change? Implementation of the Australian clinical pathway for the screening, assessment and management of anxiety and depression in adult cancer patients (ADAPT CP)Supportive Care in Cancer, 2020
- Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-upAnnals of Oncology, 2020
- Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian CancerClinical Breast Cancer, 2018
- Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi surveySupportive Care in Cancer, 2017